Volume 23, Number 1Literature ReviewsMethods for Prostate Cancer Risk Stratification: Serum-Based and Urine-Based Biomarkers for Biopsy ConsiderationAlex S. BartRyan D. T. Badre-HumeMeghan E. RobertsGriffen KempskieAlyssa N. GiannascaProstate cancer (PCa) is one of the most commonly occurring cancers in men globally. In 2024, it is estimated that there will be 99 010 PCa diagnoses and 35 250 PCa-related deaths in American patients. Given the high incidence and virulence of the disease, proper screening methods are crucial to reduce overdiagnosis and overtreatment of PCa. Using biomarkers with high tumor sensitivity and specificity is therefore crucial to effectively distinguish PCa from benign tissue.Prostate cancer
Volume 23, Number 1Treatment ReviewConsistency in Care Opportunities for Prostate CancerWanda WiltNicole SmithKatie GrantJayme NalleyJody PinkertonThrough data analysis and multiple interviews and insights, this study attempted to address the inconsistency in care for patients with prostate cancer who shared similar journey time points, demographics, and care center expertise. The Consistency of Care Project aimed to evaluate the impact of efforts to improve targeted metrics surrounding crucial clinical interventions of prostate-specific antigen monitoring, surveillance scanning, and pharmacologic interventions over a 9-month period. For comparison, 15 private urology practices of like size, patient population, and demographics were monitored. Ten of the practices benefitted from reviewed workflow training on the PPS Analytics data platform; access to a PPS Analytics Clinical Analyst, who supported education for identification of actionable patients; consistent data analysis; workflow support; and regular check-in meetings to monitor progress. The 5 control sites were monitored without additional, purposeful intervention. Outcomes support the hypothesis that inconsistency in care can begin to be addressed through focused workflows, strong navigation, and attention to key performance indicators. Attrition rate differences of 32% vs 6% improvements (reengaging patients for care who had no next appointment scheduled). On average, the experimental group increased the metastatic castration-sensitive prostate cancer diagnosis rate by 10%. However, the treatment rates measured a relative increase of 35% but an average of 11% absolute improvement at the supported sites vs 6% at the control sites. Patients with metastatic castration-resistant prostate cancer at the supported sites improved by 20%, compared with those in the control group, who improved by 4%. Care teams with strong workflows, supportive resources, and consistent care pathways—when combined with data analytics—can influence care and drive increased, measurable differences.Prostate cancerProstatic neoplasmsUrologyNeoplasmpatient navigation
Volume 2, Supplement 4SupplementEarly Diagnosis and Staging of Prostate CancerEarly Diagnosis and Staging of Prostate CancerPeter S AlbertFritz H SchroederJohn LynchJoseph C Presti Prostate cancerScreeningPelvic lymphadenectomySystematic prostate biopsy
Volume 2, Number 4Meeting ReviewsNew Urologic Strategies Explored at Jackson Hole20th Annual Jackson Hole Urologic ConferenceMichael K BrawerProstate cancerTraumaErectile dysfunctionTestisUrogynecology
Volume 2, Number 4Meeting ReviewsAdvances in Genitourinary SurgeryMeeting of the American Association of Genitourinary SurgeonsHerbert LeporProstate cancerBladder cancerErectile dysfunctionProstatectomyIncontinence
Volume 3, Number 4Review ArticlesProstate Cancer Gene Therapy--What Have We Learned and Where Are We Going?Treatment UpdateYasutomo NasuBob DjavanProstate cancerGene therapyImmunomodulatory genesSuicide genesViral vectorsOncogenes
Volume 3, Number 4Review ArticlesCurrent Clinical Applications of the In-capromab Pendetide Scan (ProstaScint® Scan, Cyt-356)Technique UpdateMisop HanAlan W PartinProstate cancerProstaScintIn-capromab pendetide scanSoft-tissuelesionsRadiolabeled monoclonal antibodyLymph nodeProstatic fossa
Volume 3, Supplement 2SupplementProstate Cancer Pathology, Screening, and EpidemiologyJoseph BatuelloFernand LabrieGary J MillerDaisaku HiranoE David CrawfordLeonard Michael GlodeProstate cancerPSAPhenotypingMetastatic cascadeDRETRUS
Volume 3, Supplement 2SupplementComplementary Medicine for Prostate Cancer: Effects of Soy and Fat ConsumptionWael A SakrMark A MoyadDaisaku HiranoGary J MillerProstate cancerComplementary medicineFatSoyAlternative medicine
Volume 3, Supplement 2SupplementProstate Cancer: Risk Assessment and Diagnostic ApproachesEduard J GamitoFernand LabrieMichael K BrawerLeonard G GomellaProstate cancerProstate biopsyIGF-ISusceptibility genesTransrectal